PRODUCT INFORMATION



Pazufloxacin (mesylate)

Item No. 29249

CAS Registry No.:	163680-77-1	
Formal Name:	10-(1-aminocyclopropyl)-9-fluoro-	
	2,3-dihydro-3-methyl-7-oxo-7H-	
	pyrido[1,2,3-de]-1,4-benzoxazine-6-	γ γ
	carboxylic acid monomethanesulfonate	H_2N
Synonyms:	Pazufloxacin methanesulfonate, T-3762	
MF:	$C_{16}H_{15}FN_2O_4 \bullet CH_3SO_3H$	
FW:	414.4	HO
Purity:	≥98%	
UV/Vis.:	λ _{max} : 239, 318 nm	•
Supplied as:	A crystalline solid	• CH ₃ SO ₃ H
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis		

Laboratory Procedures

Pazufloxacin (mesylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the pazufloxacin (mesylate) in the solvent of choice, which should be purged with an inert gas. Pazufloxacin (mesylate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of pazufloxacin (mesylate) in these solvents is approximately 1, 25, and 20 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of pazufloxacin (mesylate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of pazufloxacin (mesylate) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Pazufloxacin is a broad-spectrum synthetic fluoroquinolone antibiotic.¹ It is active against Gram-negative and Gram-positive bacteria, including clinical isolates of E. coli, K. pneumoniae, methicillin-susceptible and -resistant S. aureus, and methicillin-susceptible and -resistant S. epidermidis (MIC₉₀s = 0.05, 0.1, 0.39, 12.5, 0.39, and 6.25 µg/ml, respectively). It inhibits E. coli, P. aeruginosa, and S. aureus DNA gyrase (IC_{50} s = 0.88, 1.9, and 10.2 µg/ml, respectively) and S. aureus topoisomerase IV (IC_{50} = 24.2 µg/ml) in cell-free assays.^{1,2} In vivo, pazufloxacin is active against systemic E. coli, K. pneumoniae, and methicillin-resistant S. aureus infections in mice (ED_{50} = 0.15, 5.5, and 4.5 mg/kg, respectively).³

References

- 1. Muratani, T., Inoue, M., and Mitsuhashi, S. In vitro activity of T-3761, a new fluoroquinolone. Antimicrob. Agents Chemother. 36(10), 2293-2303 (1992).
- Takei, M., Fukuda, H., Kishii, R., et al. Target preference of 15 quinolones against Staphylococcus aureus, 2. based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45(12), 3544-3547 (2001).
- 3. Fukuoka, Y., Ikeda, Y., Yamashiro, Y., et al. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob. Agents Chemother. 37(3), 384-392 (1993).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM